The treatment schedule of various study groups and
doses are mentioned in Table 1. The dose of NR-INF-02
was administered based on the pre-clinical studies, wherein
NR-INF-02 showed significant anti-inflammatory and
analgesic activity at 90 mg/kg rat body weight (unpublished
data). The dose for glucosamine was arrived on the
basis of previous published literature